CPMG
VC Fund
Dallas, United States
CPMG is an American investment management company that is focused on the public equity markets of the U.S. CPMG is headquartered in Dallas, Texas, United States, and currently operates as a subsidiary of the Cardinal Investment Company.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 55%
Last updated:
For AI agents: llms.txt
Industries CPMG invests in
Health CareBiotechnologyMedical DeviceSaaSMarketplace
Stages CPMG invests in
Series BSeries CSeries DSeries ESeries G
Countries CPMG invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anil Parmar
|
|||
Chris White
|
|||
David Glazebrook
|
|||
James Huang
|
|||
|
John Bateman
|
|||
| See all 9 contacts → | |||
Investment Focus
Industry
- Health Care 4 (36%)
- Biotechnology 3 (27%)
- Medical Device 3 (27%)
- SaaS 2 (18%)
- Marketplace 2 (18%)
Stage
- Series B 3 (27%)
- Series C 2 (18%)
- Series D 2 (18%)
- Series E 1 (9%)
- Series G 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anil Parmar
Group Director
|
Group Director | Total investments: 0 | Find email | |
|
Chris White
Group Director
|
Group Director | Total investments: 0 | Find email | |
|
David Glazebrook
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
James Huang
China Office Manager
|
China Office Manager | Total investments: 0 | Find email | |
|
John Bateman
COO
|
COO | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ossium Health
|
Ossium is building the world's first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.The cells of the immune system are the human body’s natural defenders against disease. At Ossium, they are developing better methods of recovering, preserving, deploying these critical cells to keepdisease at bay. | $52M / Series C / Jul 25, 2023 | |
Augmedics
|
Augmedics is a provider of augmented reality (AR) surgical image guidance solutions. Augmedics seeks to improve healthcare by developing cutting-edge technologies that will revolutionize surgical treatment. The company’s first product, the xvision-spine (XVS) system, is an augmented-reality surgical navigation system designed to allow surgeons tosee and navigate inside a patient’s body during complex procedures. | $82.5M / Series D / Jun 27, 2023 | |
LeafLink
|
LeafLink is a wholesale management platform that connects cannabis brands and retailers. It helps brands and retailers who want to streamline the ordering process, simplify communication, and spend less time on busywork. With a robust online marketplace, CRM, and order management tools, LeafLink has created a centralized sales engine to helpretailers manage and grow their business. LeafLink was founded in 2015 and is headquartered in New York, New York. It serves over 1,200 brands and 3,500 retailers across 22 territories in the US and Canada | $100M / Series D / Feb 01, 2023 | |
Kindred Motorworks
|
Kindred Motorworks are marketing folks, technicians, software developers, mechanical engineers, designers, painters and car lovers | $15.6M / Venture - Series Unknown / Dec 01, 2021 | |
Provi
|
Provi is the largest online marketplace that simplifies the complex process of ordering wholesale alcohol by connecting buyers, distributors and suppliers. Active in key markets throughout the U.S., Provi's robust, online marketplace improves communication and efficiency for on- and off-premise buyers, distributors and suppliers. As of 2022,10 percent of licensed retailers in the U.S. are on the marketplace. Founded in 2016 and headquartered in Chicago, Provi has received a total of $125 million in funding, is valued at $750 million and has recently been named an Emerging Unicorn by Crunchbase. The company also received Built In Chicago's Best Places to Work recognition in 2022. In 2022, Provi joined forces with SevenFifty. | $75M / Series C / Sep 21, 2021 | |
PROCEPT BioRobotics
|
PROCEPT is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benignprostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. | $85M / Series G / Jun 30, 2021 | |
|
Provi
|
Provi is the largest online marketplace that simplifies the complex process of ordering wholesale alcohol by connecting buyers, distributors and suppliers. Active in key markets throughout the U.S., Provi's robust, online marketplace improves communication and efficiency for on- and off-premise buyers, distributors and suppliers. As of 2022,10 percent of licensed retailers in the U.S. are on the marketplace. Founded in 2016 and headquartered in Chicago, Provi has received a total of $125 million in funding, is valued at $750 million and has recently been named an Emerging Unicorn by Crunchbase. The company also received Built In Chicago's Best Places to Work recognition in 2022. In 2022, Provi joined forces with SevenFifty. | $25M / Series B / Feb 01, 2021 | |
|
PROCEPT BioRobotics
|
PROCEPT is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benignprostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. | $118M / Series E / Feb 20, 2018 | |
Theatro
|
Theatro is a software company that creates business apps for mobile IoT devices for the indoor mobile workforce. With an initial focus on the enterprise retail and hospitality market, Theatro creates a suite of productivity applications that are complimentary with other technologies (WiFi, BI systems, IOS/Android, tablets, etc.) and providescritical management command, control, and analytics to increase sales associate productivity, conversion rates, and store profitability.Theatro was founded in 2011 and is based in Richardson, Texas, United States. | $14.9M / Series B / Oct 01, 2017 | |
Apollo Endosurgery
|
Apollo Endosurgery develops medical devices for the diagnosis and treatment of gastrointestinal diseases. The company’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products include the X-Tack™ Endoscopic HeliX Tacking System, theOverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.Apollo Endosurgery was founded upon the initial work of the Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities (Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong.) Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 (Timeline) with the goal to advance the new discipline; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders. | $47.6M / Series B / Feb 06, 2012 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Marketplace Investors
40,654 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Device Investors
11,047 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
Marketplace VC Funds
26,677 investors
FAQ
What does CPMG invest in?
CPMG invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CPMG?
Public channels for CPMG include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CPMG?
The team at CPMG includes Anil Parmar (Group Director), Chris White (Group Director) and David Glazebrook (Managing Director), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
